Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Respiratory Medicine

Background:

• Fractional exhaled nitric oxide (FeNO) is an established biomarker for eosinophilic airway inflammation in asthma.
• Elevated FeNO levels are indicative of underlying inflammation, guiding asthma management strategies.

Purpose of the Study:

• To investigate if incorporating repeated FeNO measurements into asthma monitoring improves clinical outcomes in children.
• To assess the impact of FeNO-guided therapy on asthma control parameters.

Main Methods:

• A prospective, randomized, single-blind study involving 47 children with mild to moderate asthma.
• Two groups were compared: a FeNO group (therapy guided by FeNO, symptoms, lung function, and beta-agonist use) and a control group (therapy guided by symptoms, lung function, and beta-agonist use only).
• Measurements included respiratory symptoms, beta-agonist use, FEV(1)% predicted, MEF(50)% predicted, and FeNO levels over five visits in 6 weeks intervals.

Main Results:

• The FeNO group received higher doses of inhaled corticosteroids (ICS) and demonstrated significantly improved MEF(50)% predicted, indicating better small airway function.
• No significant differences were observed in the frequency of respiratory symptoms, beta-agonist use, or exacerbations between the groups.
• A FeNO cut-off of 22.9 ppb showed 80% sensitivity and 60% specificity for predicting exacerbations. FeNO correlated significantly with ICS dose, beta-agonist use, asthma symptoms, and bronchial hyperresponsiveness.

Conclusions:

• FeNO is closely related to key asthma control indicators, including ICS dosage and symptom severity.
• While FeNO-guided therapy improved small airway function in children with asthma, it did not lead to significant improvements in overall clinical asthma control markers.